Which is the active moiety of sulfasalazine in ankylosing spondylitis?: A randomized, controlled study

Arthritis and Rheumatism

Volumn 39, Issue 8, 1996, Pages 1400-1405

  Taggart, Allister ^a   Gardiner, Philip ^b   McEvoy, Frances ^a   Hopkins, Robbie ^c   Bird, Howard ^c  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

^b ALTNAGELVIN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MESALAZINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG STRUCTURE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PLASMA VISCOSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029781756     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390819     Document Type: Article

References (26)

1. Feltelius N, Hällgren R: Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 45:396-399, 1986
2. Dougados M, Boumier P, Amor B: Sulphasalazine in ankylosing spondylitis: a double-blind controlled study in 60 patients. BMJ 293:911-914, 1986
3. Nissilä M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U: Sulfasalazine in the treatment of ankylosing spondylitis: a twenty-six-week placebo-controlled clinical trial. Arthritis Rheum 31:1111-1116, 1988
4. Davis MJ, Dawes PT, Beswick E, Lewin IV, Stanworth DR: Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 28:410-413, 1989
5. Fraser SM, Sturrock RD: Evaluation of sulphasalazine in ankylosing spondylitis: an interventional study. Br J Rheumatol 29:37-39, 1990
6. Pullar T, Hunter JA, Capell HA: Which component of sulphasalazine is active in rheumatoid arthritis? BMJ 290:1535-1538, 1985
7. Neumann VC, Taggart AJ, le Gallez P, Astbury C, Hill J, Bird HA: A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol 13:285-287, 1986
8. Bennett PH, Burch TA: New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 17:453-458, 1967
9. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC: Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197-202, 1987
10. Corkill MM, Jobanputra P, Gibson T, MacFarlane DG: A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 29:41-45, 1990
11. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H: The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 32:729-733, 1993
12. Ferraz MB, Tugwell P, Goldsmith CH, Atra E: Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17:1482-1486, 1990
13. Laurent R: Are there any antirheumatic drugs that modify the course of ankylosing spondylitis? Baillieres Clin Rheumatol 4:387-400, 1990
14. Dougados M, Maetzel A, Mijiyawa M, Amor B: Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis 51:955-958, 1992
15. Neumann VC, Shinebaum R, Cooke EM, Wright V: Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. Br J Rheumatol 26:334-337, 1987
16. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I: Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: effects of sulfasalazine and other disease-modifying antirheumatic drugs. Arthritis Rheum 37:1146-1150, 1994
17. Katz KD, Hollander D: Intestinal mucosal permeability and rheumatological diseases. Baillieres Clin Rheumatol 3:271-284, 1990
18. Chapman CM, Zwillich SH: Olsalazine in ankylosing spondylitis: a pilot study. J Rheumatol 21:1699-1701, 1994
19. Smedegard G, Bjork J: Sulfasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 34 (suppl 2):7-15, 1995
20. Pinals RS: Sulfasalazine in the rheumatic disease. Semin Arthritis Rheum 17:246-259, 1988
21. Astbury C, Hill J, Bird HA: Phthalylsulphathiazole in rheumatoid arthritis. Br J Rheumatol 31:461-463, 1992
22. Comer SS, Jasin HE: In vitro immunomodulatory effects of sulphasalazine and its metabolites. J Rheumatol 15:580-586, 1988
23. Sheldon P, Webb C, Grindulis KA: Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes: clues to its action? Br J Rheumatol 27:344-349, 1988
24. Sheldon P, Pell P: Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen. Br J Clin Pharmacol 35:261-264, 1993
25. Astbury C, Hill J, Lowe JR, Campbell D, Bird HA: Methylsulphasalazine in rheumatoid arthritis. Br J Rheumatol 29:465-467, 1990
26. Webb C, Sheldon PJ: Comparative suppression of lymphocyte transformation by sulfasalazine analogues (abstract). Br J Rheumatol 28:A2-68, 1989